Publications by authors named "Fabrice Andre"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

11

Total Likes

8

Extended Reach

6,197

Social Features

3
P
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
Ian E Krop, Lorenza Mittempergher, Joseph N Paulson, Fabrice Andre, Herve Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D Gelber, Carmela Caballero, Rajith Bhaskaran

JCO Precis Oncol· January 2024

Videos about Article: user

1 2

View All Article and Social Media Activity
S
Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance.
Grigory A Puzanov, Clémence Astier, Dimitris Papakonstantinou, Mariana Quiroga Londoño, Camille Blériot, Andrey A Yurchenko, Fabrice Andre

Cancer Lett· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 immunorad conference.
Pierre-Antoine Laurent, Fabrice André, Alexandre Bobard, Desiree Deandreis, Sandra Demaria

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer.
Ghina Jardali, Littisha Lawrance, Lama Dawi, Jules Dupont, Othilie Gautier, Alexandre Bône

Diagn Interv Imaging· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novae: a graph-based foundation model for spatial transcriptomics data.
Quentin Blampey, Hakim Benkirane, Nadège Bercovici, Kevin Mulder, Grégoire Gessain

Nat Methods· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
Frédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, Kevin Tran, Lili Du, Fabrice Andre

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.
Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, Paul Gougis, Jérôme Lemonnier

Clin Pharmacol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Abderaouf Hamza, Pierre Gestraud, Maryam Karimi, Alicia Tran-Dien, Laurène Syx

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab deruxtecan in HRHER2 advanced breast cancer: a phase 2 trial.
Barbara Pistilli, Fernanda Mosele, Noemie Corcos, Livia Pierotti, Yoann Pradat, Andrea Sporchia

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.
Garazi Ruiz de Azua, Idlir Licaj, Sandrine Pinto, Julie Havas, Antonio Di Meglio

Br J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
Solenn Barraud, Sophie Vacher, Camille Schiffler, Jennifer Wong, Abderaouf Hamza

Br J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
Edith Borcoman, Bastien Cabarrou, Miguel Francisco, Frédéric Bigot, François Ghiringhelli, Fabrice Andre

Nat Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging tumour classification and treatment.
Vivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, Fabrice Andre

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases.
Julien Viot, Romain Loyon, Nawfel Adib, Pierre Laurent-Puig, Aurélien de Reyniès

EBioMedicine· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
Michele Bottosso, Renata L Sandoval, Benjamin Verret, Natalia Polidorio, Olivier Caron

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trial.
Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid

Nat Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
Morgane Lopez, Laurie Spehner, Fabrice André, Julien Viot, Evan Seffar

Breast Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.
Jean-Marie Michot, Vito Dozio, Julien Rohmer, Fanny Pommeret, Mathilde Roumier

J Proteome Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.
Lama Dawi, Younes Belkouchi, Littisha Lawrance, Othilie Gautier, Samy Ammari

Radiology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing.
Arnaud Guille, José Adélaïde, Pascal Finetti, Fabrice Andre, Daniel Birnbaum

Brief Bioinform· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, Juan Flórez-Arango, Francesco Facchinetti

Mol Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Yohann Loriot, Maud Kamal, Laurene Syx, Remy Nicolle, Celia Dupain, Fabrice Andre

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.
Yohann Loriot, Maud Kamal, Laurene Syx, Remy Nicolle, Celia Dupain, Fabrice Andre

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.
Maria Alice Franzoi, Arlindo R Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean

Lancet Reg Health Eur· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis